Skip to main content
Fig. 2 | Journal of Translational Medicine

Fig. 2

From: Efficacy and safety comparison of CAR-T and blinatumomab immunotherapy as bridge-to-transplant strategies in relapsed/refractory B cell acute lymphoblastic leukemia

Fig. 2

The Kaplan–Meier curves for GRFS of R/R B-ALL patients receiving immunotherapy as pretransplant treatments. (A) The GRFS in the entire cohort. (B) The GRFS in CAR-T group and Blinatumomab group. (C) The GRFS of PB and PB + BM subgroups in the whole cohort. (D) The GRFS of patient gender subgroups in the whole group. GRFS, graft-versus-host disease-free and relapse-free survival; R/R B-ALL, relapsed/refractory B-cell acute lymphoblastic leukemia; CAR-T, chimeric antigen receptor T-cell; PB, peripheral blood; BM, bone marrow

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us